Back

Teva begins direct NYSE trading of ordinary shares after ADS transition

Verifying
  • Teva began direct NYSE trading of ordinary shares, completing its planned ADS program transition.
  • More than 40% year-over-year growth came from AUSTEDO®, AJOVY®, and UZEDY® in 2026.
  • Teva retains the TEVA ticker on both the NYSE and Tel Aviv Stock Exchange.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.